source
- Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseasesBiogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
- FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancerThe U.S. Food and Drug Administration sent a complete response letter to Summit Therapeutics, declining to approve its bispecific antibody ivonescimab for patients with previously treated EGFR‑muta…Fierce Biotech · 3d agoRegulatoryNegative